000808420 001__ 808420
000808420 005__ 20210129222754.0
000808420 0247_ $$2doi$$a10.1002/jnr.23686
000808420 0247_ $$2WOS$$aWOS:000367066600005
000808420 037__ $$aFZJ-2016-02243
000808420 041__ $$aEnglish
000808420 082__ $$a570
000808420 1001_ $$0P:(DE-HGF)0$$aVay, S. U.$$b0
000808420 245__ $$aMinocycline mitigates the gliogenic effects of pro-inflammatory cytokines on neural stem cells
000808420 260__ $$aNew York, NY [u.a.]$$bWiley-Liss$$c2016
000808420 3367_ $$0PUB:(DE-HGF)16$$2PUB:(DE-HGF)$$aJournal Article$$bjournal$$mjournal$$s1461137996_9235
000808420 3367_ $$2DataCite$$aOutput Types/Journal article
000808420 3367_ $$00$$2EndNote$$aJournal Article
000808420 3367_ $$2BibTeX$$aARTICLE
000808420 3367_ $$2ORCID$$aJOURNAL_ARTICLE
000808420 3367_ $$2DRIVER$$aarticle
000808420 520__ $$aMobilizing endogenous neural stem cells (NSCs) in the adult brain is designed to enhance the brain's regenerative capacity after cerebral lesions, e.g., as a result of stroke. Cerebral ischemia elicits neuroinflammatory processes affecting NSCs in multiple ways, the precise mechanisms of which currently remain elusive. An inhibitory effect of minocycline on microglia activation, a hallmark of postischemic neuroinflammation, has already been demonstrated in clinical trials, showing minocycline to be safe and potentially effective in ischemic stroke. Here we investigate the direct effects of minocycline and of proinflammatory cytokines on the differentiation potential of NSCs in vitro and in vivo. Primary fetal rat NSCs were treated with minocycline plus a combination of the proinflammatory cytokines tumor necrosis factor-α, interleukin 1β, and interleukin 6. The differentiation fate of NSCs was assessed immunocytochemically. To investigate the effects of minocycline and inflammation in vivo, minocycline or lipopolysaccharides were injected intraperitoneally into adult rats, with subsequent immunohistochemistry. Minocycline alone did not affect the differentiation potential of NSCs in vivo or in vitro. In contrast, proinflammatory cytokines accelerated the differentiation of NSCs, promoting an astrocytic fate while inhibiting neurogenesis in vitro and in vivo. It is interesting to note that minocycline counteracted this cytokine-induced rapid astrocytic differentiation and restored the neurogenic and oligodendrogliogenic potential of NSCs. Data suggest that minocycline antagonizes the rapid glial differentiation induced by proinflammatory cytokines following cerebral ischemia but without having a direct effect on the differentiation potential of NSCs. Thus, minocycline constitutes a promising drug for stroke research, counteracting the detrimental effects of postischemic neuroinflammation in multiple ways.
000808420 536__ $$0G:(DE-HGF)POF3-572$$a572 - (Dys-)function and Plasticity (POF3-572)$$cPOF3-572$$fPOF III$$x0
000808420 7001_ $$0P:(DE-HGF)0$$aBlaschke, S.$$b1
000808420 7001_ $$0P:(DE-HGF)0$$aKlein, R.$$b2
000808420 7001_ $$0P:(DE-Juel1)131720$$aFink, Gereon Rudolf$$b3
000808420 7001_ $$0P:(DE-HGF)0$$aSchroeter, M.$$b4
000808420 7001_ $$0P:(DE-HGF)0$$aRueger, M. A.$$b5$$eCorresponding author
000808420 773__ $$0PERI:(DE-600)1474904-x$$a10.1002/jnr.23686$$n2$$p149-160$$tJournal of neuroscience research$$v94$$x0360-4012$$y2016
000808420 909CO $$ooai:juser.fz-juelich.de:808420$$pVDB
000808420 9101_ $$0I:(DE-588b)5008462-8$$6P:(DE-Juel1)131720$$aForschungszentrum Jülich GmbH$$b3$$kFZJ
000808420 9131_ $$0G:(DE-HGF)POF3-572$$1G:(DE-HGF)POF3-570$$2G:(DE-HGF)POF3-500$$3G:(DE-HGF)POF3$$4G:(DE-HGF)POF$$aDE-HGF$$bKey Technologies$$lDecoding the Human Brain$$v(Dys-)function and Plasticity$$x0
000808420 9141_ $$y2016
000808420 915__ $$0StatID:(DE-HGF)0200$$2StatID$$aDBCoverage$$bSCOPUS
000808420 915__ $$0StatID:(DE-HGF)1030$$2StatID$$aDBCoverage$$bCurrent Contents - Life Sciences
000808420 915__ $$0StatID:(DE-HGF)0100$$2StatID$$aJCR$$bJ NEUROSCI RES : 2013
000808420 915__ $$0StatID:(DE-HGF)0150$$2StatID$$aDBCoverage$$bWeb of Science Core Collection
000808420 915__ $$0StatID:(DE-HGF)0110$$2StatID$$aWoS$$bScience Citation Index
000808420 915__ $$0StatID:(DE-HGF)0111$$2StatID$$aWoS$$bScience Citation Index Expanded
000808420 915__ $$0StatID:(DE-HGF)9900$$2StatID$$aIF < 5
000808420 915__ $$0StatID:(DE-HGF)0310$$2StatID$$aDBCoverage$$bNCBI Molecular Biology Database
000808420 915__ $$0StatID:(DE-HGF)1050$$2StatID$$aDBCoverage$$bBIOSIS Previews
000808420 915__ $$0StatID:(DE-HGF)0300$$2StatID$$aDBCoverage$$bMedline
000808420 915__ $$0StatID:(DE-HGF)0550$$2StatID$$aNo Authors Fulltext
000808420 915__ $$0StatID:(DE-HGF)0199$$2StatID$$aDBCoverage$$bThomson Reuters Master Journal List
000808420 920__ $$lyes
000808420 9201_ $$0I:(DE-Juel1)INM-3-20090406$$kINM-3$$lKognitive Neurowissenschaften$$x0
000808420 980__ $$ajournal
000808420 980__ $$aVDB
000808420 980__ $$aUNRESTRICTED
000808420 980__ $$aI:(DE-Juel1)INM-3-20090406